{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-25-000153","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.047090+00:00","generated_at":"2026-05-16T22:26:46.599952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Editas Q3 net loss narrows to $25.1M; preclinical EDIT-401 shows >90% LDL-C reduction; cash runway extended to Q3 2027","bullets":["Net loss of $25.1M ($0.28/sh) vs $62.1M ($0.75/sh) in Q3 2024; collaboration revenue rose to $7.5M from $0.1M on BMS milestone.","R&D expenses fell 58% to $19.8M; G&A expenses fell 32% to $12.3M, both reflecting reni-cel program discontinuation.","Cash & securities $165.6M at Sept. 30; $17.8M raised via ATM in Q3; runway extended into Q3 2027, enabling EDIT-401 progression.","Preclinical data: single dose of EDIT-401 achieved ≥90% LDL-C reduction in NHPs within 48 hours; durability shown in 3-month mouse study.","On track to file IND/CTA for EDIT-401 by mid-2026; initial human proof-of-concept data expected by year-end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-25-000153","json":"https://secwatch.observer/filing/0001650664-25-000153.json","markdown":"https://secwatch.observer/filing/0001650664-25-000153.md","text":"https://secwatch.observer/filing/0001650664-25-000153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000153/0001650664-25-000153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000153/edit-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:26:46.599952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}